Exciting times for cytomegalovirus (CMV) vaccine development: Navigating the pathways toward the goal of protecting infants against congenital CMV infection

Mark R. Schleiss; Don J. Diamond

doi:10.3390/vaccines8030526

Exciting times for cytomegalovirus (CMV) vaccine development: Navigating the pathways toward the goal of protecting infants against congenital CMV infection

Mark R. Schleiss, Don J. Diamond

Pediatrics - Infectious Disease

Research output: Contribution to journal › Editorial › peer-review

8 Scopus citations

Original language	English (US)
Article number	526
Pages (from-to)	1-4
Number of pages	4
Journal	Vaccines
Volume	8
Issue number	3
DOIs	https://doi.org/10.3390/vaccines8030526
State	Published - Sep 2020

Bibliographical note

Funding Information:
Support for Mark R. Schleiss from R01 HD098866 and R01 HD079918. Don J. Diamond is partially supported by NIH-U19 AI128913, NIH-P01 CA111412, and NIH-R01 CA181045. This work was also supported by the University of South Carolina’s Disability Research and Dissemination Center (DRDC) through its Cooperative Agreement (Number 6U19DD001218) with the Centers for Disease Control and Prevention (CDC). Acknowledgments: Support from the Minnesota American Legion and Auxiliary is acknowledged.

Funding Information:
Funding: Support for Mark R. Schleiss from R01 HD098866 and R01 HD079918. Don J. Diamond is partially supported by NIH-U19 AI128913, NIH-P01 CA111412, and NIH-R01 CA181045. This work was also supported by the University of South Carolina’s Disability Research and Dissemination Center (DRDC) through its Cooperative Agreement (Number 6U19DD001218) with the Centers for Disease Control and Prevention (CDC).

Access

10.3390/vaccines8030526

OpenUrl availability

Full text

Cite this

@article{04c24b9aeef0491eb73e0172f92aa3fb,

title = "Exciting times for cytomegalovirus (CMV) vaccine development: Navigating the pathways toward the goal of protecting infants against congenital CMV infection",

author = "Schleiss, {Mark R.} and Diamond, {Don J.}",

note = "Funding Information: Support for Mark R. Schleiss from R01 HD098866 and R01 HD079918. Don J. Diamond is partially supported by NIH-U19 AI128913, NIH-P01 CA111412, and NIH-R01 CA181045. This work was also supported by the University of South Carolina{\textquoteright}s Disability Research and Dissemination Center (DRDC) through its Cooperative Agreement (Number 6U19DD001218) with the Centers for Disease Control and Prevention (CDC). Acknowledgments: Support from the Minnesota American Legion and Auxiliary is acknowledged. Funding Information: Funding: Support for Mark R. Schleiss from R01 HD098866 and R01 HD079918. Don J. Diamond is partially supported by NIH-U19 AI128913, NIH-P01 CA111412, and NIH-R01 CA181045. This work was also supported by the University of South Carolina{\textquoteright}s Disability Research and Dissemination Center (DRDC) through its Cooperative Agreement (Number 6U19DD001218) with the Centers for Disease Control and Prevention (CDC).",

year = "2020",

month = sep,

doi = "10.3390/vaccines8030526",

language = "English (US)",

volume = "8",

pages = "1--4",

journal = "Vaccines",

issn = "2076-393X",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "3",

}

TY - JOUR

T1 - Exciting times for cytomegalovirus (CMV) vaccine development

T2 - Navigating the pathways toward the goal of protecting infants against congenital CMV infection

AU - Schleiss, Mark R.

AU - Diamond, Don J.

N1 - Funding Information: Support for Mark R. Schleiss from R01 HD098866 and R01 HD079918. Don J. Diamond is partially supported by NIH-U19 AI128913, NIH-P01 CA111412, and NIH-R01 CA181045. This work was also supported by the University of South Carolina’s Disability Research and Dissemination Center (DRDC) through its Cooperative Agreement (Number 6U19DD001218) with the Centers for Disease Control and Prevention (CDC). Acknowledgments: Support from the Minnesota American Legion and Auxiliary is acknowledged. Funding Information: Funding: Support for Mark R. Schleiss from R01 HD098866 and R01 HD079918. Don J. Diamond is partially supported by NIH-U19 AI128913, NIH-P01 CA111412, and NIH-R01 CA181045. This work was also supported by the University of South Carolina’s Disability Research and Dissemination Center (DRDC) through its Cooperative Agreement (Number 6U19DD001218) with the Centers for Disease Control and Prevention (CDC).

PY - 2020/9

Y1 - 2020/9

UR - http://www.scopus.com/inward/record.url?scp=85090912583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090912583&partnerID=8YFLogxK

U2 - 10.3390/vaccines8030526

DO - 10.3390/vaccines8030526

M3 - Editorial

C2 - 32937764

AN - SCOPUS:85090912583

SN - 2076-393X

VL - 8

SP - 1

EP - 4

JO - Vaccines

JF - Vaccines

IS - 3

M1 - 526

ER -

Exciting times for cytomegalovirus (CMV) vaccine development: Navigating the pathways toward the goal of protecting infants against congenital CMV infection

Bibliographical note

Access

OpenUrl availability

Other files and links

Cite this